Because of the possibility of residual leukemia-associated genetic variants persisting after induction treatment with LDC/G-CSF, we investigated the quality and duration of molecular remission by targeted deep sequencing performed in 86 samples from 20 patients who attained morphologic remission after induction I with the LDC/G-CSF (n = 9) or SDC (n = 11) regimens. The gene discussed is CSF3; the disease is leukemia.